Cancer medicine margin cap: approval precedes list and notification
GS 2: Issues relating to development and management of Social Sector/Services relating to Health. GS 3: Indian Economy; pharmaceutical pricing and market regulation.
The government reported approval of a 30% trade-margin cap for non-scheduled anti-cancer medicines. An expert committee must finalise coverage before the pricing authority decides and notifies the intervention; projected savings remain estimates. [1]
Read full analysis →